Immunocore Completes 540-Patient Enrollment in Phase 3 TEBE-AM Melanoma Trial
Immunocore hit target enrollment of 540 patients in the Phase 3 TEBE-AM trial of tebentafusp in HLA-A*02:01-positive advanced melanoma, with topline overall survival data expected as early as year-en…